Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo - PubMed (original) (raw)
. 2003 Dec 15;63(24):8742-8.
Affiliations
- PMID: 14695189
Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo
Stina Garvin et al. Cancer Res. 2003.
Abstract
Vascular endothelial growth factor (VEGF) is considered a key mediator of tumor angiogenesis, including neovascularization in human breast cancer. High tissue VEGF levels appear to correlate with poor prognosis and decreased overall survival in node-positive and node-negative breast cancer patients. Hormonal regulation of VEGF expression has been demonstrated, and some reports indicate that tamoxifen, a partial estrogen receptor agonist, increases VEGF mRNA in breast cancer cells. These results appear to contradict the efficacy of tamoxifen as an adjuvant for estrogen-dependent breast cancer, yet clinical data show that tamoxifen prevents metastasis and increases overall survival. In this study, we confirmed previous studies showing that intracellular levels of VEGF in vitro increased in response to tamoxifen to levels similar to those observed after estrogen treatment. To further study hormonal effects on the release of VEGF, we used microdialysis to sample the extracellular space, where VEGF is biologically active, in solid tumors in situ. We show for the first time that tamoxifen decreased extracellular VEGF in vivo in solid MCF-7 tumors in nude mice. These in vivo findings were confirmed in vitro where extracellular VEGF in the cell culture medium was decreased significantly by tamoxifen treatment. Furthermore, we illustrate that microdialysis is a viable method that may be applied in human breast tissue to detect soluble VEGF in situ released by the tumor.
Similar articles
- Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo.
Nilsson UW, Dabrosin C. Nilsson UW, et al. Cancer Res. 2006 May 1;66(9):4789-94. doi: 10.1158/0008-5472.CAN-05-4012. Cancer Res. 2006. PMID: 16651433 - Tamoxifen decreases extracellular TGF-beta1 secreted from breast cancer cells--a post-translational regulation involving matrix metalloproteinase activity.
Nilsson UW, Jönsson JA, Dabrosin C. Nilsson UW, et al. Exp Cell Res. 2009 Jan 1;315(1):1-9. doi: 10.1016/j.yexcr.2008.10.015. Epub 2008 Oct 28. Exp Cell Res. 2009. PMID: 18996114 - Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo.
Bergman Jungeström M, Thompson LU, Dabrosin C. Bergman Jungeström M, et al. Clin Cancer Res. 2007 Feb 1;13(3):1061-7. doi: 10.1158/1078-0432.CCR-06-1651. Clin Cancer Res. 2007. PMID: 17289903 - Triple-negative breast cancer: role of antiangiogenic agents.
Greenberg S, Rugo HS. Greenberg S, et al. Cancer J. 2010 Jan-Feb;16(1):33-8. doi: 10.1097/PPO.0b013e3181d38514. Cancer J. 2010. PMID: 20164688 Review. - Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer.
Delli Carpini J, Karam AK, Montgomery L. Delli Carpini J, et al. Angiogenesis. 2010 Mar;13(1):43-58. doi: 10.1007/s10456-010-9163-3. Epub 2010 Mar 14. Angiogenesis. 2010. PMID: 20229258 Review.
Cited by
- Breast density and estradiol are associated with distinct different expression patterns of metabolic proteins in normal human breast tissue in vivo.
Ekstrand J, Abrahamsson A, Lundberg P, Dabrosin C. Ekstrand J, et al. Front Oncol. 2023 Mar 29;13:1128318. doi: 10.3389/fonc.2023.1128318. eCollection 2023. Front Oncol. 2023. PMID: 37064098 Free PMC article. - Obesity and cancer-extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases.
Pellegata NS, Berriel Diaz M, Rohm M, Herzig S. Pellegata NS, et al. Cancer Metastasis Rev. 2022 Sep;41(3):517-547. doi: 10.1007/s10555-022-10058-y. Epub 2022 Sep 8. Cancer Metastasis Rev. 2022. PMID: 36074318 Free PMC article. Review. - Breast Density and Estradiol Are Major Determinants for Soluble TNF-TNF-R Proteins in vivo in Human Breast Tissue.
Ekstrand J, Zemmler M, Abrahamsson A, Lundberg P, Forsgren M, Dabrosin C. Ekstrand J, et al. Front Immunol. 2022 Mar 30;13:850240. doi: 10.3389/fimmu.2022.850240. eCollection 2022. Front Immunol. 2022. PMID: 35432372 Free PMC article. - New Advances in Targeted Therapy of HER2-Negative Breast Cancer.
An J, Peng C, Xie X, Peng F. An J, et al. Front Oncol. 2022 Mar 4;12:828438. doi: 10.3389/fonc.2022.828438. eCollection 2022. Front Oncol. 2022. PMID: 35311116 Free PMC article. Review. - Active Rap1-mediated inhibition of choroidal neovascularization requires interactions with IQGAP1 in choroidal endothelial cells.
Ramshekar A, Wang H, Kunz E, Pappas C, Hageman GS, Chaqour B, Sacks DB, Hartnett ME. Ramshekar A, et al. FASEB J. 2021 Jul;35(7):e21642. doi: 10.1096/fj.202100112R. FASEB J. 2021. PMID: 34166557 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical